Journal of Clinical Oncology, Vol 16, 584-588, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant

R Little, RE Wittes, DL Longo and WH Wilson
Medicine Branch, National Cancer Institute, Bethesda, MD 20892, USA.

PURPOSE: Bone marrow transplant (BMT) can cure recurrent Hodgkin's disease, but more than half of patients will progress and require additional treatment. When this occurs, there are no curative options and palliative therapy is usually indicated. In such patients, we have routinely used long-term vinblastine therapy because of its relatively low toxicity and high activity. PATIENTS AND METHODS: We retrospectively reviewed the charts of all patients with Hodgkin's disease who relapsed after autologous BMT since 1991. Of 23 patients, 16 received vinblastine; we also include our index case, who began vinblastine following relapse in 1987. Patients received vinblastine 4 to 6 mg/m2 every 1 to 2 weeks, and continued until evidence of disease progression. RESULTS: The 17 patients in this report had a median age of 31 years, performance status of 2, had received a median of three prior regimens, and 12 (71%) patients were advanced stage. Ten (59%) patients had objective responses, of which two (12%) were complete (CR) and eight (47%) were partial (PR). Two additional patients without measurable disease clinically improved for more than 6 months, and 1 patient had stable disease for more than 18 months. With a median follow-up of 20.4 months, the median event-free (EFS) and overall survival were 8.3 and 38.8 months, respectively. The two complete responders remain in remission at 4.6+ and 9+ years. Vinblastine was well tolerated with 3% of cycles associated with fever and neutropenia, and no cumulative or chronic toxicity. CONCLUSION: Vinblastine provides effective palliation with low toxicity in recurrent Hodgkin's disease following transplant. These results suggest that long-term vinblastine therapy may be potentially curative and should be considered as initial therapy for such patients.

This article has been cited by other articles:

				M. Crump Management of Hodgkin Lymphoma in Relapse after Autologous Stem Cell Transplant Hematology, January 1, 2008; 2008(1): 326 - 333. [Abstract] [Full Text] [PDF]

				B. J. Byrne and J. P. Gockerman Salvage Therapy in Hodgkin's Lymphoma Oncologist, February 1, 2007; 12(2): 156 - 167. [Abstract] [Full Text] [PDF]

				S. D. Young, M. Whissell, J. C.S. Noble, P. O. Cano, P. G. Lopez, and C. J. Germond Phase II Clinical Trial Results Involving Treatment with Low-Dose Daily Oral Cyclophosphamide, Weekly Vinblastine, and Rofecoxib in Patients with Advanced Solid Tumors. Clin. Cancer Res., May 15, 2006; 12(10): 3092 - 3098. [Abstract] [Full Text] [PDF]

				H. Bredenfeld, J. Franklin, L. Nogova, A. Josting, S. Fries, V. Mailander, J. Oertel, V. Diehl, and A. Engert Severe Pulmonary Toxicity in Patients With Advanced-Stage Hodgkin's Disease Treated With a Modified Bleomycin, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone, and Gemcitabine (BEACOPP) Regimen Is Probably Related to the Combination of Gemcitabine and Bleomycin: A Report of the German Hodgkin's Lymphoma Study Group J. Clin. Oncol., June 15, 2004; 22(12): 2424 - 2429. [Abstract] [Full Text] [PDF]

				I. Radman, N. Basic, B. Labar, J. Kovacevic, I. Aurer, V. Bogdanic, S. Zupancic-Salek, D. Nemet, J. Jakic-Razumovic, M. Mrsic, et al. Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience) Ann. Onc., October 1, 2002; 13(10): 1650 - 1655. [Abstract] [Full Text] [PDF]